Case Reports in Oncological Medicine / 2015 / Article / Tab 1

Case Report

Metastatic Extramammary Paget’s Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature

Table 1

Percent of cases by subtype with biomarker aberration and comparison of total EMPD versus MPD.

Primary tumor siteIHCISHSequencing
ARBCRPERHer2MGMTMRP1PD-1PD-L1PDGFRPRPTEN*RRM1*TLE3TOP2ATOPO1TS*cMYC EGFRHer2BRCA2PIK3CA

Anus ()0%NT 0%0%0%50%NT NT NT 0%50% 50%NT100%0%100%NT50%NT NT NT
Scrotum ()100%NT 100%0%100%NT100%100%NT0%0% 0%100%100%100%0%0%NT0%100%100%
Vulva ()67%67%22%44%44%75%NT NT 67%11%89%67%0%44%44%89%0%0%0%NT0%
All EMPD ()58%67%25%33%42%70%100%100%67%8%75%58%50%58%42%83%0%11%0%100%50%
MPD ()50%33%71%36%40%75%NT NT 25%43%67%100%100%20%80%100%100%0%25%NT 100%

Biomarker and technology used are shown for each subtype, as percent of total cases. A total of EMPDs are also compared to MPD. Percent in each box refers to overexpression of target proteins except for PTEN*, RRM1*, and TS*, where the percent refers to underexpression of the target. Genes in which no mutation was found: ABL1, AKT1, ALK, ATM, BRAF, BRCA1, BRCA2, CDH1, c-KIT, cMET, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FLT3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, JAK2, JAK3, KDR, KRAS, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, SMO, STK11, TP53, and VHL.
IHC, immunohistochemistry; ISH, fluorescence in situ hybridization.